5 peptides that can help you live longer

Peptide research has moved from the fringe of biohacking into serious geroscience labs. Five peptides in particular — Epitalon, MOTS-c, BPC-157, Thymosin Alpha-1, and GHK-Cu — are being studied specifically for their effects on the biological drivers of aging: telomere maintenance, mitochondrial function, tissue repair, immune resilience, and cellular signaling. None are FDA-approved longevity drugs. All are actively investigated, and each has a defensible mechanistic story worth understanding.

1. Epitalon — telomerase and the pineal axis

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide derived from epithalamin, a pineal gland extract first characterized by Russian gerontologist Vladimir Khavinson. In cell culture, Epitalon upregulates telomerase activity and extends telomere length in human somatic cells — the biological "caps" whose shortening is a hallmark of aging. Longitudinal Russian cohort studies over 6–12 years reported reduced mortality and improved circadian and endocrine markers in elderly patients on cyclic Epitalon. The evidence base outside those cohorts is still small, and no U.S. randomized controlled trial has replicated the mortality findings — but the mechanism (telomerase induction, melatonin rhythm restoration) is one of the most direct anti-aging pathways any peptide targets.

2. MOTS-c — the exercise-mimetic mitochondrial peptide

MOTS-c is a 16-amino-acid peptide encoded not in the nuclear genome but in mitochondrial DNA. It acts as a metabolic regulator, activating AMPK — the same "energy sensor" pathway triggered by exercise, caloric restriction, and metformin. In mouse models, MOTS-c administration improves insulin sensitivity, reduces age-related weight gain, and extends healthspan. Human MOTS-c levels fall with age and are lower in people with metabolic disease. It is one of the few peptides where the geroscience mechanism is genuinely upstream — you are not treating a symptom of aging, you are supplementing a signal the mitochondria themselves stop producing.

3. BPC-157 — systemic tissue repair

BPC-157 is a synthetic pentadecapeptide derived from a protective sequence in human gastric juice. It has been studied for over 25 years in animal models of soft tissue injury, tendon and ligament repair, gut barrier dysfunction, and vascular healing. The mechanistic picture: BPC-157 upregulates growth factor expression (VEGF, FGF), stabilizes the nitric oxide system, and appears to accelerate angiogenesis in injured tissue. Longevity is not just about extending life — it is about staying functional. BPC-157 is a repair peptide, and the case for including it in longevity thinking rests on that: an aging body that heals faster from micro-injuries stays capable longer.

4. Thymosin Alpha-1 — immune resilience with age

Thymosin Alpha-1 is a naturally occurring 28-amino-acid peptide produced by the thymus. Its role is regulating T-cell maturation and immune balance. As the thymus involutes with age — a process well documented from the 30s onward — endogenous Thymosin Alpha-1 production falls, and this immunosenescence is a major contributor to increased infection risk, poorer vaccine response, and rising cancer incidence with age. Thymosin Alpha-1 is approved in more than 35 countries for hepatitis B and as an immune adjuvant, and it has been studied for post-viral recovery, chronic infection, and immune reconstitution. For longevity, its promise is straightforward: restoring immune vigor is one of the most consequential interventions available.

5. GHK-Cu — the "regenerative" copper peptide

GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) that binds copper and circulates in human plasma. Levels drop roughly 60% between age 20 and age 60. Beyond its well-known cosmetic effect on skin collagen, GHK-Cu has been shown in gene expression studies to modulate over 4,000 human genes — many involved in wound healing, tissue remodeling, and anti-inflammatory signaling. It is one of the most striking examples of a peptide whose declining levels track the aging phenotype almost line-for-line. Whether restoring it changes lifespan is unproven; that its decline correlates with tissue aging is not.

What the evidence does not show

None of these peptides have been shown in large randomized human trials to extend lifespan. The most rigorous data lives in mouse models, cell culture, and small clinical cohorts — often from Russia, China, or European centers. That does not mean the compounds are unserious; it means the honest answer to "will this make me live longer" is "we do not yet know, and the mechanisms are plausible enough to be studied harder." The FDA has increased scrutiny on compounded peptides in 2026, and Kindr Health only evaluates peptide therapy as part of a physician-supervised protocol — not as consumer supplements.

How Kindr approaches longevity peptides

Our Longevity service evaluates peptide therapy alongside cardiometabolic risk, hormone status, sleep architecture, and body composition. Peptides are one tool among many — after the fundamentals (protein, resistance training, sleep, cardiometabolic care, and, where indicated, hormone therapy) are optimized. If you are considering a peptide protocol, the right question is not "which peptide should I buy" but "which biological system is aging fastest in me, and what tool best addresses it?" That is the conversation a menopause- and longevity-trained clinician is built to have.

The bottom line

Five peptides — Epitalon, MOTS-c, BPC-157, Thymosin Alpha-1, and GHK-Cu — sit at the intersection of real geroscience and real clinical curiosity. None replaces the fundamentals. Each targets a distinct biological driver of aging with mechanistic plausibility and some human data. The most useful frame is not "anti-aging" but "resilience": the goal is a body that heals faster, signals better, and defends itself longer.

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026